Key points: GLP-1s (glucagon-like peptide-1 receptor agonists) support type 2 diabetes by reducing appetite and supporting weight loss alongside their effects on the pancreas GLP-1-assisted programmes lead to a clinically significant weight loss of 10% or more, which can significantly reduce complications associated with obesity Combining semaglutide with lifestyle interventions leads to significantly more weight loss than lifestyle interventions alone, with 87% of participants losing more than 10% of their body weight Semaglutide is more effective at supporting weight loss than liraglutide Tirzepatide is more effective than semaglutide at reducing weight, with all three doses of tirzepatide leading to more significant weight loss than 1mg of semaglutide The higher doses of tirzepatide (10mg and 15mg) might reduce weight by 5.15kg more than 2mg of semaglutide, while there appears to be no difference between 5mg of tirzepatide and 2mg of semaglutide 3) Side effects and safety All medications have possible side effects, particularly if you live with other health conditions
BPC-157 is a synthetic pentadecapeptide consisting of a defined 15-amino-acid sequence
Final Thoughts Tesamorelin, CJC-1295 (with and without DAC), and sermorelin all engage the GHRH receptor mechanism but differ substantially in structural features, half-life, and research properties
Sermorelin is a peptidecifically, a "growth hormone secretagogue" that stimulates your pituitary gland
I have type 2 diabetes, OSA, or MASH
Take it before or in between meals, early in the day, rather than at night
